Synchron has high hopes that after successfully implanting the first minimally invasive neural brain-computer interface device in a human, it will eventually be able to give a "voice" to patients, including paralyzed individuals, who are unable to communicate. The company is conducting clinical trials and is hoping to use the data to apply for US FDA approval of the Stentrode device.

The company launched in Silicon Valley on April 21 with plans to develop a device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.

The company launched in Silicon Valley on April 21 with plans to develop a device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.